EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm

Aya Ghosn, Khalil Bassam, Mohammad Al Zein, Suzanne A Nasser, Gianfranco Pintus, Ali H Eid

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01925-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Aya Ghosn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering, Newyork, NY, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptors, Adrenergic, beta, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Qatar University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Its development is influenced by several risk factors, including smoking, diets rich in red meat, and the effects of stress-related hormones such as epinephrine and norepinephrine. These hormones act through β-adrenergic receptors (β-ARs), which are present on CRC cells and are associated with cancer-promoting processes such as increased cell growth, invasion, blood vessel formation, and accelerated disease progression. Notably, β-ARs blockers have shown potential in slowing CRC progression, pointing to a promising therapeutic strategy. This review explores the main signaling pathways through which β-ARs contribute to cancer development and how various risk factors may influence these mechanisms. We also provide an overview of current preclinical and clinical studies on β-AR blockers in CRC, identify existing gaps in knowledge, and propose directions for future research to optimize therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsReceptors, Adrenergic, betaAdrenergic beta-AntagonistsHumansAnimalsSignal TransductionRisk FactorsDisease Progression

Stichwörter der Autor:innen

COX-2ChemotherapyCyclinMalignancyVEGFmicroRNA, Adrenergic

Substanzen

Receptors, Adrenergic, betaAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Memorial Sloan Kettering, Newyork, NY, USA.
  • Cleveland Clinic, Cleveland, OH, USA.
  • Keele University, Staffordshire, UK.
  • University of Sassari, Sassari, Italy.
  • Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar. ali.eid@qu.edu.qa.

Förderung

  • NCI NIH HHS
  • Qatar University

Zitieren

APA

Ghosn, A., Bassam, K., Al Zein, M., Nasser, S. A., Pintus, G., & Eid, A. H. (2025). Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01925-5

Vancouver

Ghosn A, Bassam K, Al Zein M, Nasser SA, Pintus G, Eid AH. Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01925-5

BibTeX
@article{Ghosn2025,
  author = {Ghosn, Aya and Bassam, Khalil and Al Zein, Mohammad and Nasser, Suzanne A and Pintus, Gianfranco and Eid, Ali H},
  title = {Pharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01925-5}
}
Kostenlos starten →